Investigational gene therapy licensed for Parkinson’s disease: industry news round-up

Written by Sharon Salt, Editor

This week’s industry news round-up reveals the latest updates around spinal muscular atrophy, Parkinson’s disease and acute stroke. Find out more about our selection of the highlights below. Our pick of the headlines include: Roche discontinues work on olesoxime for spinal muscular atrophy Axovant licenses investigational gene therapy for Parkinson’s disease Biogen enters agreement to acquire TMS-007 for acute stroke Roche discontinues work on olesoxime for spinal muscular atrophy Roche (Basel, Switzerland) has disclosed that it has ended work on olesoxime – an oral compound intended to protect motor neurons – for the treatment of spinal muscular atrophy (SMA), having...

To view the full article, please register now for access

It's completely free